Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top

18-09-2024 | Chronic Kidney Disease | News

EASD 2024

Finerenone: cardiorenal benefits for broad patient population

Login to get access

MedNet.nl: A pooled analysis of 3 studies with finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), shows positive results for a broad patient population. FINE-HEART suggests cardiorenal benefits for patients at high risk for cardiovascular, renal, and metabolic disease. The results of FINE-HEART were published in Nature Medicine.

Related topics

EASD 2024 rotated-square
Type 2 Diabetes rotated-square
Circulatory Disease rotated-square
Metabolic Disease and Nutrition rotated-square
Finerenone rotated-square
Heart Failure rotated-square
Diabetic Nephropathy rotated-square
Diabetes and Cardiac Diseases rotated-square
Diabetes and Cardiac Diseases rotated-square
Prediabetes rotated-square

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

Read more

Weight loss with new obesity drug amycretin

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

Liraglutide reduces BMI for young children with obesity

» View more highlights on the EASD 2024 hub page

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits